financetom
Business
financetom
/
Business
/
ARS Pharmaceuticals Files for Approval of Experimental Allergic Reaction Treatment in Canada, UK
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
ARS Pharmaceuticals Files for Approval of Experimental Allergic Reaction Treatment in Canada, UK
Jan 6, 2025 8:21 AM

11:06 AM EST, 01/06/2025 (MT Newswires) -- ARS Pharmaceuticals ( SPRY ) said Monday it has filed for approval of the neffy epinephrine nasal spray for the treatment of type I allergic reactions in Canada and the UK on behalf of its licensing partner, ALK-Abello.

The company said it is assessing its intranasal epinephrine technology to treat acute flares in patients with chronic urticaria. It intends to initiate a phase 2b clinical trial early this year.

ARS Pharmaceuticals ( SPRY ) also said its license deal with ALK will provide them exclusive rights for any new indication in the licensed territories under the agreement.

Shares of the company declined more than 1% in recent trading activity.

Price: 10.99, Change: -0.21, Percent Change: -1.83

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved